Trial Profile
Raltegravir intensification in antiretroviral-treated patients exhibiting a suboptimal CD4+ T cell response
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Therapeutic Use
- 06 Mar 2013 Results presented at the 20th Conference on Retroviruses and Opportunistic Infections.
- 10 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Feb 2010 Primary endpoint results presented at the 17th Conference on Retroviruses and Opportunistic Infections